On the stock market since 2013, it operates in the world of health and science. It has 106 employees. Now — the numbers.
This is an established company with proven profits.
Average growth of 64% a year over the last 4 years. Red columns mark years that ended in a loss.
If every debt were paid off today, $2.2B would still be left in the vault — a solid cushion for hard times.
angles, checked one by one.
The 2 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
The stock trades 47% below its peak. The market has trimmed its expectations for the company.
The net profit margin is 38% — still a thick cushion, though costs have been eating into it lately.
Over the last 3 years, sales grew about 67% a year on average.
There is $2.8B in the vault; even if every debt were paid off, $2.2B would remain.
Since the drop from its peak, buyer appetite hasn’t come back. Council score: 0/10.
On our five-subject report card, DMTRF sits near the top of the class. A high grade doesn’t mean “guaranteed win” — it means “the evidence looks strong for now.”
The takeaway: DMTRF is an established business that has proven its profits for years. The real debate isn’t the quality of the business — it’s whether the price paid for the stock is too high.